What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders

Simply Wall St.06-18

Earlier in June 2026, GH Research PLC reported full Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all 10 patients, improved maternal ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644727716?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-06-18 06:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644727716","market":"hk","top_or_hot":-1,"title":"What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>Earlier in June 2026, GH Research PLC reported full Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all 10 patients, improved maternal ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/what-gh-research-ghrss-phase-2a-postpartum-depression-breakt\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-18 06:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/what-gh-research-ghrss-phase-2a-postpartum-depression-breakt><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in June 2026, GH Research PLC reported full Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all 10 patients, improved maternal ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/what-gh-research-ghrss-phase-2a-postpartum-depression-breakt\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/what-gh-research-ghrss-phase-2a-postpartum-depression-breakt","article_id":"2644727716","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/what-gh-research-ghrss-phase-2a-postpartum-depression-breakt","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644727716","pubTimestamp":1781735050,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in June 2026, GH Research PLC reported full Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all 10 patients, improved maternal functioning, and a favorable safety profile, with findings published in The Journal of Clinical Psychiatry and highlighted at the upcoming CINP 2026 congress.\nAn additional practical insight from the trial was that drug levels in breast milk supported only a brief interruption of breastfeeding around...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4196":"保健护理服务","BK4588":"碎股","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念","BK4007":"制药","GHRS":"GH Research PLC","GH":"Guardant Health Inc."},"translate_title":"GH Research(GHRS)2a期产后抑郁症突破对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1.5,"GHRS":1.5},"content_text":"Earlier in June 2026, GH Research PLC reported full Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all 10 patients, improved maternal functioning, and a favorable safety profile, with findings published in The Journal of Clinical Psychiatry and highlighted at the upcoming CINP 2026 congress. An additional practical insight from the trial was that drug levels in breast milk supported only a brief interruption of breastfeeding around GH001 dosing, directly addressing a key concern for many postpartum patients. Next, we’ll examine how GH001’s rapid-onset remission data in postpartum depression may influence GH Research’s broader investment narrative. We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementWhat Is GH Research's Investment Narrative?To own GH Research, you have to believe that ultra‑rapid antidepressant relief can support a focused, niche psychiatry franchise built around GH001 in treatment‑resistant and postpartum depression, despite zero revenue and ongoing losses. The new postpartum Phase 2a data reinforces that core idea by extending GH001’s profile into another high‑need setting, with peer‑reviewed remission and safety results that can strengthen the scientific and commercial story rather than move near‑term numbers. In the short term, the more tangible catalysts still sit with GH001’s treatment‑resistant depression program, upcoming CINP 2026 readouts and how the company uses its fresh US$317,500,022 of equity capacity, while key risks remain trial setbacks, regulatory outcomes and future dilution. The PPD data adds credibility, but it does not remove those execution and funding questions. However, one risk in particular may matter more than the recent clinical headlines.\n\nInsights from our recent valuation report point to the potential overvaluation of GH Research shares in the market.Exploring Other PerspectivesGHRS 1-Year Stock Price Chart Two fair values from the Simply Wall St Community span US$3.95 to US$39.50, showing how far apart individual expectations can be. When you set that against GH Research’s lack of revenue and dependence on successful GH001 trials, it underlines why many market participants focus on both upside potential and funding or clinical risk before taking a view.Explore 2 other fair value estimates on GH Research - why the stock might be worth as much as 98% more than the current price!The Verdict Is YoursDisagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your GH Research research is our analysis highlighting 2 important warning signs that could impact your investment decision.Our free GH Research research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GH Research's overall financial health at a glance.Looking For Alternative Opportunities?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Find 47 companies with promising cash flow potential yet trading below their fair value.Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644727716","isCrawlerRequest":true}